Gefarnate

Summary

Gefarnate (CHEMBL2105085) is a phase-3 clinical-stage small molecule (ATC A02BX07); indicated across 6 conditions including gastroesophageal reflux disease and peptic ulcer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A02BX07 (+1 more)
• Indications: 6 conditions
• Clinical trials: 3
• Chemistry: 400.6 Da · C27H44O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105085
Name	Gefarnate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5282182
ATC	A02BX07, A02BX77
Molecular formula	C27H44O2
Molecular weight	400.6
InChIKey	ZPACYDRSPFRDHO-ROBAGEODSA-N

SMILES: CC(=CCC/C(=C/CC/C(=C/CCC(=O)OC/C=C(\C)/CCC=C(C)C)/C)/C)C

IUPAC name: [(2E)-3,7-dimethylocta-2,6-dienyl] (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate

Also known as: DA 688, DA-688, Gefanil, Gefarnate, Gefarnato, GEFARNATE, SID144206536, SID170465908, GERANYL-FARNESYLACETATE, Geranyl-farnesylacetate; Gefarnate

Patent coverage: 484 distinct patent families (1,748 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
gastroesophageal reflux disease	3	MONDO:0007186	EFO:0003948
peptic ulcer disease	3	MONDO:0004247	HP:0004398
cerebrovascular disorder	3	MONDO:0011057	EFO:0003763
duodenal ulcer	3	MONDO:0005412	EFO:0004607
gastric ulcer	3	MONDO:0001126	EFO:0009454
coronary artery disorder	2	MONDO:0005010	EFO:0001645

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00762359	PHASE3	TERMINATED	A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers
NCT00787254	PHASE3	COMPLETED	Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs
NCT03610321	PHASE2/PHASE3	UNKNOWN	Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).